Aviva’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$549M Buy
2,162,709
+30,312
+1% +$7.06M 0.81% 18
2026
Q1
$521M Buy
2,132,397
+58,390
+3% +$13.6M 0.87% 17
2025
Q4
$429M Buy
2,074,007
+162,565
+9% +$32.1M 0.72% 16
2025
Q3
$354M Buy
1,911,442
+110,157
+6% +$18.9M 0.64% 22
2025
Q2
$275M Buy
1,801,285
+118,521
+7% +$18.2M 0.57% 23
2025
Q1
$279M Buy
1,682,764
+231,825
+16% +$36.3M 0.67% 24
2024
Q4
$210M Sell
1,450,939
-78,294
-5% -$12.1M 0.55% 29
2024
Q3
$248M Buy
1,529,233
+35,737
+2% +$5.69M 0.64% 26
2024
Q2
$218M Buy
1,493,496
+253,797
+20% +$37.7M 0.61% 27
2024
Q1
$196M Buy
1,239,699
+24,966
+2% +$3.97M 0.65% 24
2023
Q4
$190M Buy
1,214,733
+112,877
+10% +$17.3M 0.68% 23
2023
Q3
$172M Sell
1,101,856
-85,828
-7% -$14.2M 0.72% 24
2023
Q2
$197M Buy
1,187,684
+231,184
+24% +$37.3M 0.8% 16
2023
Q1
$148M Sell
956,500
-28,085
-3% -$4.53M 0.67% 14
2022
Q4
$174M Buy
984,585
+162,472
+20% +$28.1M 0.86% 10
2022
Q3
$134M Sell
822,113
-38,904
-5% -$6.58M 0.77% 11
2022
Q2
$153M Buy
861,017
+122,803
+17% +$21.9M 0.81% 12
2022
Q1
$131M Sell
738,214
-119,430
-14% -$20.3M 0.65% 19
2021
Q4
$147M Sell
857,644
-81,477
-9% -$13.3M 0.62% 25
2021
Q3
$152M Sell
939,121
-71,155
-7% -$12.1M 0.68% 24
2021
Q2
$166M Buy
1,010,276
+14,138
+1% +$2.34M 0.73% 19
2021
Q1
$164M Buy
996,138
+21,920
+2% +$3.55M 0.8% 20
2020
Q4
$153M Buy
974,218
+9,156
+0.9% +$1.35M 0.8% 20
2020
Q3
$144M Sell
965,062
-35,178
-4% -$5.21M 0.85% 17
2020
Q2
$141M Sell
1,000,240
-40,080
-4% -$5.84M 0.88% 15
2020
Q1
$136M Sell
1,040,320
-684
-0.1% -$97K 1% 13
2019
Q4
$152M Sell
1,041,004
-1,256
-0.1% -$170K 0.92% 17
2019
Q3
$135M Sell
1,042,260
-102,645
-9% -$13.5M 0.91% 18
2019
Q2
$159M Sell
1,144,905
-37,115
-3% -$5.14M 1.1% 13
2019
Q1
$165M Buy
1,182,020
+2,814
+0.2% +$377K 1.11% 13
2018
Q4
$152M Sell
1,179,206
-316,955
-21% -$44.2M 1.13% 13
2018
Q3
$207M Sell
1,496,161
-67,318
-4% -$8.95M 1.13% 12
2018
Q2
$190M Sell
1,563,479
-20,446
-1% -$2.55M 1.12% 13
2018
Q1
$203M Sell
1,583,925
-129,859
-8% -$17.6M 1.24% 8
2017
Q4
$239M Sell
1,713,784
-216,383
-11% -$30.1M 1.36% 6
2017
Q3
$251M Sell
1,930,167
-13,802
-0.7% -$1.83M 1.35% 6
2017
Q2
$257M Sell
1,943,969
-79,237
-4% -$10.1M 1.44% 5
2017
Q1
$252M Sell
2,023,206
-83,017
-4% -$9.92M 1.44% 5
2016
Q4
$243M Sell
2,106,223
-43,583
-2% -$5.03M 1.45% 5
2016
Q3
$254M Buy
2,149,806
+197,583
+10% +$24M 1.58% 4
2016
Q2
$237M Buy
1,952,223
+63,383
+3% +$7.2M 1.62% 4
2016
Q1
$204M Buy
1,888,840
+28,357
+2% +$2.94M 1.52% 5
2015
Q4
$191M Buy
1,860,483
+199,495
+12% +$20.1M 1.45% 3
2015
Q3
$155M Sell
1,660,988
-95,965
-5% -$9.28M 1.28% 5
2015
Q2
$171M Sell
1,756,953
-74,495
-4% -$7.46M 1.21% 8
2015
Q1
$184M Buy
1,831,448
+351,874
+24% +$35.8M 1.26% 5
2014
Q4
$155M Sell
1,479,574
-4,848
-0.3% -$511K 1.2% 7
2014
Q3
$158M Sell
1,484,422
-1,896
-0.1% -$197K 1.25% 5
2014
Q2
$155M Buy
1,486,318
+59,446
+4% +$6.01M 1.19% 7
2014
Q1
$140M Buy
1,426,872
+125,910
+10% +$11.7M 1.14% 9
2013
Q4
$119M Buy
1,300,962
+63,453
+5% +$5.85M 1% 13
2013
Q3
$107M Buy
1,237,509
+164,162
+15% +$14.7M 0.94% 14
2013
Q2
$92.2M Buy
+1,073,347
New +$91.1M 0.93% 16

Other funds holding JNJ

Aviva's JNJ Position: Q2 2026 in Review

Aviva increased its Johnson & Johnson (JNJ) stake by 1.4% in Q2 2026, buying an estimated $7.06M and bringing the position to 2,162,709 shares worth $549M. The position accounts for 0.81% of the portfolio, ranked #18.

Aviva first reported a position in JNJ in Q2 2013 and has held it in 53 quarters since. 4,649 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Aviva held 2,162,709 shares of Johnson & Johnson worth $549M as of Q2 2026.
  • Aviva bought 30,312 Johnson & Johnson shares in Q2 2026, an estimated $7.06M.
  • Johnson & Johnson made up 0.81% of Aviva's portfolio in Q2 2026, its #18 holding.
  • Aviva first reported a position in Johnson & Johnson in Q2 2013 and has held it in 53 quarters since.
  • 4,649 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.